ERBB2 and breast carcinoma: Nonetheless, a controversial finding showed that there is no advantage of neoadjuvant cisplatin (pCR rate of 18%) over an anthracycline (doxorubicin) and cyclophosphamide (AC-based regimen, pCR rate of 26%), after surgery, in patients with HER2-negative, BRCA1-associated breast cancer, whether HER-positive, HER-negative, or TNBC [68].